Simultaneous targeting of estrogen receptor and HER2 in breast cancer

References

• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med.360, 790–800 (2009).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature406, 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Untch M, Gelber RD, Jackisch C et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann. Oncol.19, 1090–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Brufsky A, Lembersky B, Schiffman K et al. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin. Breast Cancer6, 247–252 (2005).
   PubMedGoogle Scholar
• Bhargava R, Beriwal S, Dabbs DJ et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer116, 1431–1439 (2010).
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst.101, 736–750 (2009).
   PubMed Web of Science ®Google Scholar
• Jones A. Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why? Ann. Oncol.14, 1697–1704 (2003).
   PubMedGoogle Scholar
• Dowsett M, Harper-Wynne C, Boeddinghaus I et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res.61, 8452–8458 (2001).
   PubMed Web of Science ®Google Scholar
• Fujita T, Doihara H, Kawasaki K et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br. J. Cancer94, 247–252 (2006).
   PubMed Web of Science ®Google Scholar
• Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell100, 387–390 (2000).
   PubMed Web of Science ®Google Scholar
• Azim H, Azim HA Jr. Targeting HER-2/neu in breast cancer: as easy as this! Oncology74, 150–157 (2008).
   PubMed Web of Science ®Google Scholar
• Xia W, Gerard CM, Liu L et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene24, 6213–6221 (2005).
   PubMed Web of Science ®Google Scholar
• Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene23, 646–653 (2004).
   PubMed Web of Science ®Google Scholar
• Spector NL, Xia W, Burris H 3rd et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol.23, 2502–2512 (2005).
   PubMed Web of Science ®Google Scholar
• Xia W, Bisi J, Strum J et al. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res.66, 1640–1647 (2006).
   PubMed Web of Science ®Google Scholar
• Nicholson RI, McClelland RA, Robertson JF, Gee JM. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr. Relat. Cancer6, 373–387 (1999).
   PubMed Web of Science ®Google Scholar
• Pietras RJ, Arboleda J, Reese DM et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene10, 2435–2446 (1995).
   PubMed Web of Science ®Google Scholar
• Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev.29, 217–233 (2008).
   PubMed Web of Science ®Google Scholar
• Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin. Cancer Res.11, 865s–870s (2005).
   PubMed Web of Science ®Google Scholar
• Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science270, 1491–1494 (1995).
   PubMed Web of Science ®Google Scholar
• Hong SH, Privalsky ML. The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol. Cell. Biol.20, 6612–6625 (2000).
   PubMed Web of Science ®Google Scholar
• Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol.20, 5041–5047 (2000).
   PubMedGoogle Scholar
• Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology103, 1742–1751 (1978).
   PubMed Web of Science ®Google Scholar
• Horwitz KB, McGuire WL. Specific progesterone receptors in human breast cancer. Steroids25, 497–505 (1975).
   PubMed Web of Science ®Google Scholar
• Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. Steroids253, 2223–2228 (1978).
   Google Scholar
• Gross GE, Clark GM, Chamness GC, McGuire WL. Multiple progesterone receptor assays in human breast cancer. Cancer Res.44, 836–840 (1984).
   PubMed Web of Science ®Google Scholar
• Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br. J. Cancer79, 1564–1571 (1999).
   PubMedGoogle Scholar
• Cui X, Zhang P, Deng W et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol. Endocrinol.17, 575–588 (2003).
   PubMed Web of Science ®Google Scholar
• Petz LN, Ziegler YS, Schultz JR, Nardulli AM. Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol. Endocrinol.18, 521–532 (2004).
   PubMedGoogle Scholar
• Arpino G, Weiss H, Lee AV et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl Cancer Inst.97, 1254–1261 (2005).
   PubMed Web of Science ®Google Scholar
• Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst.96, 926–935 (2004).
   PubMed Web of Science ®Google Scholar
• Macedo LF, Sabnis G, Brodie A. Aromatase inhibitors and breast cancer. Ann. NY Acad. Sci.1155, 162–173 (2009).
   PubMedGoogle Scholar
• Long BJ, Jelovac D, Thiantanawat A, Brodie AM. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin. Cancer Res.8, 2378–2388 (2002).
   PubMed Web of Science ®Google Scholar
• Jelovac D, Sabnis G, Long BJ et al. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res.65, 5380–5389 (2005).
   PubMedGoogle Scholar
• Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer34, 791–808 (1998).
   PubMed Web of Science ®Google Scholar
• De Laurentiis M, Arpino G, Massarelli E et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin. Cancer Res.11, 4741–4748 (2005).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol.19, 2596–2606 (2001).
   PubMed Web of Science ®Google Scholar
• Paridaens RJ, Dirix LY, Beex LV et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J. Clin. Oncol.26, 4883–4890 (2008).
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol.19, 3808–3816 (2001).
   PubMed Web of Science ®Google Scholar
• Lipton A, Ali SM, Leitzel K et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol.20, 1467–1472 (2002).
   PubMed Web of Science ®Google Scholar
• Lipton A, Ali SM, Leitzel K et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J. Clin. Oncol.21, 1967–1972 (2003).
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Tao Y, Young O et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J. Clin. Oncol.24, 3019–3025 (2006).
   PubMed Web of Science ®Google Scholar
• De Placido S, De Laurentiis M, Carlomagno C et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin. Cancer Res.9, 1039–1046 (2003).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Houghton J, Iden C et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according estrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol.17, 818–826 (2006).
   PubMed Web of Science ®Google Scholar
• Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer98, 1802–1810 (2003).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med.350, 1081–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol.23, 5138–5147 (2005).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med.361, 766–776 (2009).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Allred C, Knox J et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J. Clin. Oncol.26, 1059–1065 (2008).
   PubMed Web of Science ®Google Scholar
• Rasmussen BB, Regan MM, Lykkesfeldt AE et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomized trial. Lancet Oncol.9, 23–28 (2008).
   PubMed Web of Science ®Google Scholar
• Sabnis G, Schayowitz A, Goloubeva O et al. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res.69, 1416–1428 (2009).
   PubMedGoogle Scholar
• Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res.65, 18–25 (2005).
   PubMed Web of Science ®Google Scholar
• Piccart M. Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer. Clin. Breast Cancer8(Suppl. 3), S100–S113 (2008).
   Google Scholar
• du Manoir JM, Francia G, Man S et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin. Cancer Res.12, 904–916 (2006).
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol.18, 977–984 (2007).
   PubMed Web of Science ®Google Scholar
• Xia W, Bacus S, Hegde P et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl Acad. Sci. USA103, 7795–7800 (2006).
   PubMed Web of Science ®Google Scholar
• Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst.95, 353–361 (2003).
   PubMed Web of Science ®Google Scholar
• Marcom PK, Isaacs C, Harris L et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res. Treat.102, 43–49 (2007).
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol.20, 719–726 (2002).
   PubMed Web of Science ®Google Scholar
• Baselga J, Carbonell X, Castaneda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin. Oncol.23, 2162–2171 (2005).
   PubMed Web of Science ®Google Scholar
• Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized Phase III TAnDEM study. J. Clin. Oncol.27, 5529–5537 (2009).
   PubMed Web of Science ®Google Scholar
• Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol.27, 5538–5546 (2009).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Guarneri V. Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. Expert Rev. Anticancer Ther.9, 1549–1557 (2009).
   PubMed Web of Science ®Google Scholar
• Knowlden JM, Hutcheson IR, Jones HE et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology144, 1032–1044 (2003).
   PubMed Web of Science ®Google Scholar
• Finn RS, Press M, Dering J et al. Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: biomarker results of EGF30008. 2009 ASCO Annual Meeting, Poster discussion. J. Clin. Oncol.27(Suppl.), 15 (2009) (Abstract 1018).
   Google Scholar
• Amir E, Ocana A, Seruga B et al. Lapatinib and HER2 status: results of a meta-analysis of randomized Phase III trials in metastatic breast cancer. Cancer Treat. Rev.36, 410–415 (2010).
   PubMed Web of Science ®Google Scholar
• Finn RS, Press MF, Dering J et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J. Clin. Oncol.27, 3908–3915 (2010).
   Google Scholar
• Cristofanilli M, Valero V, Mangalik A et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin. Cancer Res.16, 1904–1914 (2010).
   PubMed Web of Science ®Google Scholar
• Gutteridge E, Agrawal A, Nicholson R et al. The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a Phase II study. Int. J. Cancer126, 1806–1816 (2009).
   Google Scholar
• Polychronis A, Sinnett HD, Hadjiminas D et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with estrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled Phase II randomized trial. Lancet Oncol.6, 383–391 (2005).
   PubMed Web of Science ®Google Scholar
• Smith IE, Walsh G, Skene A et al. A Phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol.25, 3816–3822 (2007).
   PubMed Web of Science ®Google Scholar
• Green MD, Francis PA, Gebski V et al. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann. Oncol.20, 1813–1817 (2009).
   PubMedGoogle Scholar
• Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist9(Suppl. 3), 20–26 (2004).
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Zhang B et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res.65, 11118–11128 (2005).
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell6, 117–127 (2004).
   PubMed Web of Science ®Google Scholar